{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.6","value":"316.8"},{"groupId":"OG001","spread":"45.8","value":"611.0"},{"groupId":"OG002","spread":"58.2","value":"794.1"},{"groupId":"OG003","spread":"10.2","value":"505.8"},{"groupId":"OG004","spread":"25","value":"1278.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"4"}],"units":"Participants"}],"description":"Pharmacokinetic (PK) evaluation was performed on plasma samples obtained weekly for the first six weeks of the study and then on day 1 of each additional cycle to assess pre-treatment trough concentrations of MM-121. Non-compartmental analysis (NCA) was performed to calculate standard PK parameters, including the maximum observed concentration (Cmax). Serum levels of MM-121 were measured at a central lab using an enzyme-linked immunosorbent assay (ELISA). Data is presented per dose level of MM-121 (12 mg/kg, 20 mg/kg, or 40/20 mg/kg) and per study part (Part 1 or Part 2)","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"MM-121 mg/kg plus cetuximab at either 400/200 mg/m2 or 400/250 mg/m2","id":"OG000","title":"Part 1: 12 mg/kg"},{"description":"MM-121: 20 mg/kg Plus cetuximab at either 400/200 mg/m2 or 400/250 mg/m2","id":"OG001","title":"Part 1: 20 mg/kg"},{"description":"MM-121: 40 mg/kg loading dose followed by 20 mg/kg weekly maintenance doses Plus cetuximab at either 400/200 mg/m2 or 400/250 mg/m2","id":"OG002","title":"Part 1: 40/20 mg/kg"},{"description":"MM-121: 20 mg/kg plus cetuximab at 400/250 mg/m2 plus irinotecan at 180 mg/m2","id":"OG003","title":"Part 2: 20 mg/kg"},{"description":"MM-121: 40 mg/kg loading dose followed by 20 mg/kg weekly maintenance doses plus cetuximab 400/250 mg/m2 plus irinotecan 180 mg/m2","id":"OG004","title":"Part 2: 40/20 mg/kg"}],"paramType":"GEOMETRIC_MEAN","reportingStatus":"POSTED","timeFrame":"Collections taken for all patients at Cycle 1, Week 1 at pre-infusion, at the end of the infusion, and 2.5, 4, 6 and 24 hours after starting the infusion of MM-121","title":"Pharmacokinetics","type":"SECONDARY","unitOfMeasure":"ug/mL"}